Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
2001 1
2004 1
2005 3
2007 3
2008 4
2009 1
2010 5
2011 1
2012 1
2013 1
2018 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

20 results
Results by year
Filters applied: . Clear all
Page 1
Low-Dose Naltrexone (LDN)-Review of Therapeutic Utilization.
Toljan K, Vrooman B. Toljan K, et al. Med Sci (Basel). 2018 Sep 21;6(4):82. doi: 10.3390/medsci6040082. Med Sci (Basel). 2018. PMID: 30248938 Free PMC article. Review.
This dose is termed ultra low-dose naltrexone/naloxone (ULDN). It has been of use in postoperative control of analgesia by reducing the need for the total amount of opioids following surgery, as well as ameliorating certain side-effects of opioi …
This dose is termed ultra low-dose naltrexone/naloxone (ULDN). It has been of use in postoperative contro …
Oxytrex: an oxycodone and ultra-low-dose naltrexone formulation.
Webster LR. Webster LR. Expert Opin Investig Drugs. 2007 Aug;16(8):1277-83. doi: 10.1517/13543784.16.8.1277. Expert Opin Investig Drugs. 2007. PMID: 17685875 Review.
Oxytrex (Pain Therapeutics, Inc.) is an oral opioid that combines a therapeutic amount of oxycodone with an ultra-low dose of the antagonist naltrexone. Animal data indicate that this combination minimizes the development of physical dependence and ana …
Oxytrex (Pain Therapeutics, Inc.) is an oral opioid that combines a therapeutic amount of oxycodone with an ultra-low dose
Ultra-low dose naltrexone attenuates chronic morphine-induced gliosis in rats.
Mattioli TA, Milne B, Cahill CM. Mattioli TA, et al. Mol Pain. 2010 Apr 16;6:22. doi: 10.1186/1744-8069-6-22. Mol Pain. 2010. PMID: 20398374 Free PMC article.
In this study we demonstrate that ultra-low dose naltrexone attenuates glial activation, which may contribute to its effects on attenuating tolerance. ...Astrocyte and microglial immuno-labelling was attenuated in rats co-administered ultra-l
In this study we demonstrate that ultra-low dose naltrexone attenuates glial activation, which may contribute to …
Ultra-low dose naltrexone enhances cannabinoid-induced antinociception.
Paquette J, Olmstead MC. Paquette J, et al. Behav Pharmacol. 2005 Dec;16(8):597-603. doi: 10.1097/00008877-200512000-00001. Behav Pharmacol. 2005. PMID: 16286810
As opioid and cannabinoid systems interact, this study investigated whether ultra-low dose naltrexone also influences cannabinoid-induced antinociception. Separate groups of Long-Evans rats were tested for antinociception following an injection of vehi …
As opioid and cannabinoid systems interact, this study investigated whether ultra-low dose naltrexone also influ …
Ultra-low-dose naltrexone suppresses rewarding effects of opiates and aversive effects of opiate withdrawal in rats.
Olmstead MC, Burns LH. Olmstead MC, et al. Psychopharmacology (Berl). 2005 Sep;181(3):576-81. doi: 10.1007/s00213-005-0022-7. Epub 2005 Oct 12. Psychopharmacology (Berl). 2005. PMID: 16010543
RATIONALE: Ultra-low-dose opioid antagonists enhance opiate analgesia and attenuate tolerance and withdrawal. OBJECTIVES: To determine whether ultra-low-dose naltrexone (NTX) coadministration alters the rewarding effects of opiates …
RATIONALE: Ultra-low-dose opioid antagonists enhance opiate analgesia and attenuate tolerance and withdrawal. OBJECTIVE …
Ultra-low-dose naltrexone reduces the rewarding potency of oxycodone and relapse vulnerability in rats.
Leri F, Burns LH. Leri F, et al. Pharmacol Biochem Behav. 2005 Oct;82(2):252-62. doi: 10.1016/j.pbb.2005.08.008. Epub 2005 Sep 21. Pharmacol Biochem Behav. 2005. PMID: 16182352
Ultra-low-dose opioid antagonists have been shown to enhance opioid analgesia and alleviate opioid tolerance and dependence. Our present studies in male Sprague-Dawley rats assessed the abuse potential of oxycodone+ultra-low-dose naltr
Ultra-low-dose opioid antagonists have been shown to enhance opioid analgesia and alleviate opioid tolerance and depend
Oxycodone plus ultra-low-dose naltrexone attenuates neuropathic pain and associated mu-opioid receptor-Gs coupling.
Largent-Milnes TM, Guo W, Wang HY, Burns LH, Vanderah TW. Largent-Milnes TM, et al. J Pain. 2008 Aug;9(8):700-13. doi: 10.1016/j.jpain.2008.03.005. Epub 2008 May 12. J Pain. 2008. PMID: 18468954 Free PMC article.
Repeated administration of oxycodone alone or in combination with ultra-low-dose naltrexone (NTX) was assessed on the SNL-induced MOR-G(s) coupling as well as on neuropathic pain behavior. ...PERSPECTIVE: The current study investigates whether Oxytrex …
Repeated administration of oxycodone alone or in combination with ultra-low-dose naltrexone (NTX) was assessed o …
Ultra-low dose naltrexone potentiates the anticonvulsant effect of low dose morphine on clonic seizures.
Honar H, Riazi K, Homayoun H, Sadeghipour H, Rashidi N, Ebrahimkhani MR, Mirazi N, Dehpour AR. Honar H, et al. Neuroscience. 2004;129(3):733-42. doi: 10.1016/j.neuroscience.2004.08.029. Neuroscience. 2004. PMID: 15541894
However, ultra-low dose naltrexone could not increase the maximal anticonvulsant effect of morphine (1-3 mg/kg), possibly due to a ceiling effect. The proconvulsant effects of morphine on seizure threshold were minimally altered by ultra-low
However, ultra-low dose naltrexone could not increase the maximal anticonvulsant effect of morphine (1-3 mg/kg), …
The cannabinoid anticonvulsant effect on pentylenetetrazole-induced seizure is potentiated by ultra-low dose naltrexone in mice.
Bahremand A, Shafaroodi H, Ghasemi M, Nasrabady SE, Gholizadeh S, Dehpour AR. Bahremand A, et al. Epilepsy Res. 2008 Sep;81(1):44-51. doi: 10.1016/j.eplepsyres.2008.04.010. Epub 2008 May 27. Epilepsy Res. 2008. PMID: 18502613
Surprisingly, both the analgesic and anticonvulsant effects of opioids are enhanced by ultra-low doses (nanomolar to picomolar) of the opioid antagonist naltrexone and as opioid and cannabinoid systems interact, it has been shown that ultra-low
Surprisingly, both the analgesic and anticonvulsant effects of opioids are enhanced by ultra-low doses (nanomolar to picomolar …
Potentiation of buprenorphine antinociception with ultra-low dose naltrexone in healthy subjects.
Hay JL, La Vincente SF, Somogyi AA, Chapleo CB, White JM. Hay JL, et al. Eur J Pain. 2011 Mar;15(3):293-8. doi: 10.1016/j.ejpain.2010.07.009. Epub 2010 Aug 21. Eur J Pain. 2011. PMID: 20728384 Clinical Trial.
The aim of the current investigation was to determine whether buprenorphine antinociception could be enhanced with the addition of ultra-low dose naltrexone, using a range of dose ratios. A repeated-measures, double-blind, cross-over trial was u …
The aim of the current investigation was to determine whether buprenorphine antinociception could be enhanced with the addition of ultra
20 results